Acute Severe Pancolitis After Initiation of a Calcitonin Gene-Related Peptide Receptor Antagonist: A Case Report Authors: Abhimati Ravikulan, James Falvey, Jan Kubovy Published: 2026 ABSTRACT ABSTRACTCalcitonin gene-related peptide receptor antagonists (CGRP-RA) are increasingly prescribed for migraine prophylaxis. Gastrointestinal side effects have been described, but association with inflammatory bowel disease (IBD) is reported rarely. A 50-year-old woman with well-controlled ulcerative proctitis developed a severe flare shortly after commencing a CGRP-RA (atogepant). She presented with abdominal pain and diarrhea. Investigations showed elevated inflammatory markers, predominantly right sided colitis on computer tomography scan, as well as endoscopic and histological evidence of severe pancolitis. Treatment with intravenous steroids was ineffective, but she responded to infliximab and discontinuation of the CGRP antagonist. She was well at follow-up 3 months later. CGRP-RA may can be associated with IBD relapse or de novo disease. We present a case of acute flare with change in phenotype of disease. Clinicians should exercise caution when prescribing CGRP-RA in patients with known IBD. INTRODUCTION Drug-associated colitis and inflammatory bowel disease (IBD)–like injury are increasingly recognized across diverse therapeutic classes. Well-described examples include nonsteroidal anti-inflammatory drugs, immune checkpoint inhibitors, and biologic agents used in autoimmune conditions.1,2 With expanding the use of novel targeted therapies, postmarketing surveillance has become essential to identify rare but clinically significant gastrointestinal inflammatory complications. Calcitonin gene-related peptide (CGRP) pathway therapies, including monoclonal antibodies and small-molecule receptor antagonists (RAs) (gepants), are now widely prescribed for migraine prevention. CGRP plays a central role in trigemino-vascular activation and neurogenic inflammation in migraine pathophysiology.3 CGRP-RAs, such as atogepant, reduce migraine frequency by inhibiting CGRP-mediated vasodilation and nociceptive transmission. Beyond the central nervous system, CGRP is extensively expressed in the gastrointestinal tract, where it regulates mucosal blood flow, intestinal motility, epithelial barrier integrity, and immune modulation.4 Common gastrointestinal adverse effects reported with CGRP-pathway therapies include constipation, nausea, and abdominal discomfort.5 However, inflammatory complications have been rarely described. A recent case series reported systemic inflammatory events temporally associated with CGRP monoclonal antibodies, including autoimmune and inflammatory manifestations, highlighting the need for vigilance regarding potential immune-mediated effects.6 Emerging human data further support biological plausibility. Serum β-CGRP levels have been shown to correlate with disease activity in patients with IBD, suggesting a protective immunomodulatory role of CGRP in intestinal inflammation.7 Experimental models also demonstrate that CGRP signaling mitigates colonic inflammation and supports mucosal repair. Here, we present the first case of acute severe steroid-refractory pancolitis occurring shortly after initiation of a small molecule CGRP (atogepant) in a patient with previously stable ulcerative proctitis. CASE REPORT We present a 50-year-old Caucasian woman, nonsmoker, with a background of IBD and chronic migraines. Her IBD was diagnosed as isolated moderate proctitis (MAYO score 2) (Figure 1). Histology at diagnosis showed chronic inflammation of the rectum with cryptitis, crypt abscesses, and mucosal distortion without granulomas. The terminal ileum and colon proximal to rectum was uninvolved with normal histology. Her disease was managed with oral mesalazine, and she remained in clinical remission for 4 years. She was under the care of neurology for long-standing chronic migraines. Her other long-term medication included citalopram. She had no history of nonsteroidal anti-inflammatory medication use or hormonal therapy. Index colonoscopy showing Mayo 2 proctitis. She was commenced on the CGRP-RA atogepant (Aquipta, developed by AbbVie in China and Ireland) at a standard dose of 60 mg daily for the management of refractory chronic migraines. Two weeks after commencing this medication, she developed progressive diarrhea (up to 10 bowel motions daily), rectal bleeding, and abdominal pain. On presentation to hospital, she was afebrile, with a heart rate of 98 beats per minute, dehydrated and hypotensive with a blood pressure of 99/72 mm Hg, requiring IV fluid resuscitation. Her abdomen was soft and generally tender but without peritonism. Laboratory results showed elevated C-reactive protein of 102 mg/L, normal white cell count, hemoglobin of 118 g/L, and albumin of 21 g/L. Stool cultures were negative for bacterial, viral, and Clostridium difficile infection. Computer tomography scan of her abdomen showed moderate right-sided colonic wall thickening and pericolonic fat stranding reflecting a moderate right-sided colitis (Figures 2 and 3). Her small bowel appeared normal, and there was no evidence complication such as toxic megacolon or perforation. Inpatient flexible sigmoidoscopy revealed mild proctitis (Mayo 1) (Figure 4) with severe inflammation in splenic flexure and transverse colon (Mayo 3) (Figure 5). Biopsy confirmed severe active inflammation and was negative for cytomegalovirus infection. A diagnosis of acute severe colitis was made based on these findings. Computer tomography of the abdomen: Transverse plane showing inflamed ascending colon with pericolic fat stranding. Sagittal plane showing inflamed ascending colon with pericolic fat stranding. Flexible sigmoidoscopy showing Mayo 3 transverse colitis. Flexible sigmoidoscopy showing Mayo 1 distal rectum. She was commenced on intravenous hydrocortisone at 100 mg every 6 hours, daily prophylactic dose of subcutaneous enoxaparin, and atogepant has been stopped. Her symptoms progressed despite intravenous steroids, mirrored by rising inflammatory markers over 3 days. Repeat computer tomography of the abdomen showed persistent right-sided colitis without complications. She was at high risk of a colectomy according to the Travis criteria, and treatment was consequently escalated to include infliximab at 5 mg/kg.8 Her symptoms improved thereafter, and she was discharged on day 7 postinitiation of infliximab on oral steroid weaning course. Outpatient follow-up 3 months later found her to be in clinical remission on infliximab maintenance and thiopurine cotherapy. She remained off atogepant. DISCUSSION Drug-induced inflammatory bowel disease or IBD-like colitis is increasingly recognized across a range of therapeutic drug classes. It is commonly associated with nonsteroidal anti-inflammatory drugs, immune checkpoint inhibitors (such as nivolumab and ipilimumab), and other biologic agents used in autoimmune conditions.1,2 As described in the introduction, CGRP-RA are highly effective for migraine prophylaxis because CGRP is a key neuropeptide involved in trigemino-vascular activation, neurogenic inflammation, and vasodilation; central processes in migraine pathophysiology. By blocking the CGRP receptor or ligand, these agents reduce cranial vasodilation and nociceptive transmission, thereby alleviating migraine frequency and severity.3 However, CGRP is also widely expressed throughout the gastrointestinal tract, where it exerts essential physiological functions. Within the enteric nervous system, CGRP promotes smooth muscle relaxation, regulates intestinal motility, enhances mucosal blood flow, and supports epithelial integrity through its vasodilatory and anti-inflammatory effects.4 Antagonism of CGRP signaling can therefore disrupt these protective mechanisms. Reduced mucosal perfusion may lead to local ischemia, impaired epithelial repair, and increased susceptibility to injury, while diminished enteric neuronal signaling alters motility and barrier function.5 Collectively, these changes can predispose to mucosal inflammation and ulceration, explaining gastrointestinal adverse events such as constipation, diarrhea, and, in rare instances, colitis. Atogepant is orally administered small-molecule CGRP-RA. It reaches peak plasma concentration about 1-2 hours after dosing.9 It has a half-life of 11 hours and reaches steady-state plasma levels within 2-3 days of initiation.10–13 Therefore, in our case, any pharmacodynamic effects (including on the gut) would have been established making the temporal relationship between initiation and onset of symptoms plausible. Several published reports describe new-onset colitis temporally associated with CGRP-RA therapy. Hansen et al reported a case of a 33-year-old woman who developed bloody diarrhea and biopsy-proven colitis within 2 weeks of starting erenumab (another CGRP-RA) with complete resolution after drug discontinuation.14 More recently, a case of pan-colitis secondary to erenumab was reported, with endoscopic and histologic features of ischemic-type colitis, improving after withdrawal of the agent and corticosteroid treatment.15 By contrast, our case differs in several key aspects: It involves atogepant, an oral small-molecule RA rather than a monoclonal antibody. The patient had preexisting ulcerative proctitis in sustained remission, rather than de novo colitis. There was rapid proximal extension from isolated proctitis to pancolitis. The episode was acute severe and steroid-refractory, requiring infliximab rescue therapy. In light of this case and emerging evidence, our center has submitted a report to the Center for Adverse Reactions Monitoring. Given the expanding use of CGRP-pathway therapies, clinicians should be aware of possible inflammatory gastrointestinal complications, particularly in patients with known IBD. Careful risk–benefit assessment and close monitoring for symptom exacerbation are warranted. Reporting to pharmacovigilance systems remains essential, and reporting such cases help to better define its incidence and risk factors. DISCLOSURES Author contributions: A. Ravikulan involved in original drafting and writing of article. J. Falvey involved in drafting and editing. J. Kubovy involved in article editing and case report supervisor. A. Ravikulan is the article guarantor. Financial disclosure: None to report. Previous presentation: Presented as a poster at the New Zealand Society of Gastroenterology Annual Scientific Meeting, November 26–28, 2025, Christchurch, NZ. Informed consent was obtained for this case report.